Neuronetics, Inc.

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
2.53 ^USD	-3.07%		-1.17%	-12.76%

May. 15	Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents	CI
May. 14	William Blair Upgrades Neuronetics to Outperform From Market Perform	MT

Neuronetics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

May 04, 2021 at 06:30 am EDT

Neuronetics, Inc. provided revenue guidance for the second quarter of 2021. For the second quarter of 2021, the company expects revenue in the range of $14 million to $15 million.

Latest news about Neuronetics, Inc.

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents	May. 15	CI
William Blair Upgrades Neuronetics to Outperform From Market Perform	May. 14	MT
Transcript : Neuronetics, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (STIM) NEURONETICS Reports Q1 Revenue $17.4M	May. 07	MT
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024	May. 07	CI
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	Apr. 10	CI
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	Mar. 28	CI
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21	Mar. 25	DJ
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise	Mar. 25	MT
Neuronetics, Inc. Announces Clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy	Mar. 25	CI
Neuronetics, Inc. Announces 5-Year Exclusive Partnership with Transformations Care Network	Mar. 07	CI
Transcript : Neuronetics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Earnings Flash (STIM) NEURONETICS Reports Q4 Revenue $20.3M	Mar. 05	MT
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 05	CI
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System	Feb. 12	CI
Top Premarket Gainers	Jan. 25	MT
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023	Jan. 08	CI
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory	Dec. 18	CI
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan	Dec. 04	CI
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements	Nov. 13	CI
Transcript : Neuronetics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M	Nov. 07	MT

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-30 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Neuronetics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.61 USD

Average target price

7 USD

Spread / Average Target

+168.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEURONETICS, INC.	-12.76%	78.23M
THERMO FISHER SCIENTIFIC	+11.91%	227B
DANAHER CORPORATION	+15.46%	197B
INTUITIVE SURGICAL, INC.	+18.58%	141B
BOSTON SCIENTIFIC CORPORATION	+30.36%	110B
SIEMENS HEALTHINEERS AG	+0.65%	64.15B
EDWARDS LIFESCIENCES CORPORATION	+17.74%	53.72B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.82%	51.75B
AGILENT TECHNOLOGIES, INC.	+11.23%	45.2B
GE HEALTHCARE TECHNOLOGIES INC.	+5.73%	37.37B

Other Advanced Medical Equipment & Technology

Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Neuronetics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Latest news about Neuronetics, Inc.

Chart Neuronetics, Inc.

Company Profile

Income Statement Evolution

Ratings for Neuronetics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology